Alleviating Effect of Active Hexose Correlated Compound (AHCC) on Chemotherapy-Related Adverse Events in Patients with Unresectable Pancreatic Ductal Adenocarcinoma
Alleviating Effect of Active Hexose Correlated Compound (AHCC) on Chemotherapy-Related Adverse Events in Patients with Unresectable Pancreatic Ductal Adenocarcinoma
复制标题
活性己糖相关化合物 (AHCC) 对不可切除的胰腺导管腺癌患者化疗相关不良事件的缓解作用
DOI：
--
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
M. Kon
中科院分区：
文献类型：
--
作者：
H. Yanagimoto;S. Satoi;Tomohisa Yamamoto;S. Hirooka;S. Yamaki;M. Kotsuka;Hironori Ryota;T. Michiura;Kentaro Inoue;Y. Matsui;K. Tsuta;M. Kon
摘要本研究旨在确定活性己糖相关化合物（AHCC），一种从培养的担子菌中提取的功能性食物，是否具有减轻接受化疗的不可切除的胰腺导管腺癌（PDAC）患者不良事件的潜力。将接受吉西他滨治疗（GEM）作为一线化疗的不可切除PDAC患者前瞻性地根据AHCC摄入（AHCC组，n = 35）或未摄入（对照组，n = 40）分为2组。AHCC组口服AHCC 6.0g，连用2mo。比较AHCC组和对照组的血液学和非血液学毒性。与对照组相比，GEM给药期间AHCC组的C反应蛋白（CRP）升高和白蛋白下降均受到显著抑制（P = 0.0012，P = 0.0007）。AHCC组中GEM引起味觉障碍的发生率较低（17% vs. 56%，P = 0.0007）。化疗期间改良格拉斯哥预后评分（mGPS）3级的频率在AHCC组（14%）中显著低于对照组（53%，P = 0.0005）。AHCC摄入可有效减少与化疗相关的不良事件，并可能有助于在GEM给药期间维持PDAC患者的QOL。
ABSTRACT The present study was conducted to determine whether active hexose correlated compound (AHCC), a functional food extracted from cultured basidiomycetes, possesses the potential to attenuate adverse events in unresectable pancreas ductal adenocarcinoma (PDAC) patients receiving chemotherapy. Unresectable PDAC patients receiving gemcitabine treatment (GEM) as the first-line chemotherapy were prospectively divided into 2 groups according to AHCC intake (AHCC group, n = 35) or not (control group, n = 40). The patients in the AHCC group ingested 6.0 g of AHCC for 2 mo. Hematological and nonhematological toxicity was compared between the AHCC and control groups. The C-reactive protein (CRP) elevation and albumin decline of the AHCC group were significantly suppressed as compared to the control group during the GEM administration (P = 0.0012, P = 0.0007). Patients in the AHCC group had less frequency of taste disorder caused by GEM (17% vs. 56%, P = 0.0007). Frequency of grade 3 in the modified Glasgow Prognostic Score (mGPS) during chemotherapy was found significantly less in the AHCC group (14%) than the control group (53%, P = 0.0005). AHCC intake can be effective in reducing the adverse events associated with chemotherapy and may contribute to maintaining the QOL of patients with PDAC during GEM administration.
影响因子：
3.5
作者：
Trotti, A;Colevas, AD;Rubin, P
通讯作者：
Rubin, P